Hjem › Leiomyosarkom › Massachusetts › Boston
Leiomyosarkom kliniske forsøg i Boston, MA
5 studier for Leiomyosarkom søger deltagere på steder i og omkring Boston (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RekruttererFase 3
- Dana-Farber/Harvard Cancer Center, Boston
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
RekruttererFase 1
- Dana-Farber Cancer Institute, Boston
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
RekruttererFase 1/2
- Dana Farber Cancer Institute, Boston
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RekruttererFase 1/2
- Dana Farber Cancer Institute, Boston
Metastatic Leiomyosarcoma Biomarker Protocol
RekruttererObservationsstudie
- Dana- Farber, Boston
Leiomyosarkom forsøg i andre byer
- Houston, TX7 studier
- Santa Monica, CA4 studier
- Chicago, IL4 studier
- Rochester, MN3 studier
- Nashville, TN3 studier
- Columbus, OH3 studier
- Ann Arbor, MI3 studier
- New York City, NY3 studier
- St. Louis, MO3 studier
- Aurora, CO3 studier
- Queens, NY3 studier
Andre studier i Boston
- Brystkræft111 studier
- Ikke-småcellet lungecancer90 studier
- Kræft (alle typer)86 studier
- Colorektal kræft63 studier
- Metastatisk cancer63 studier
- Lungecancer62 studier
- Ægstockræft61 studier
- Prostatakræft59 studier
- Depression52 studier
- Livmoderslimhindekræft50 studier
- Hjertesvigt44 studier
- Akut myeloid leukæmi44 studier
Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.